Boston Private Wealth LLC reduced its stake in Stryker Corporation (NYSE:SYK) by 15.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,412 shares of the medical technology company’s stock after selling 9,758 shares during the period. Boston Private Wealth LLC’s holdings in Stryker Corporation were worth $7,552,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of SYK. BlackRock Inc. grew its stake in Stryker Corporation by 2,526.4% in the 1st quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after acquiring an additional 21,140,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Stryker Corporation by 5.2% in the 1st quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock worth $3,083,382,000 after acquiring an additional 1,161,688 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Stryker Corporation by 41.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock worth $184,759,000 after acquiring an additional 414,715 shares in the last quarter. SG Americas Securities LLC grew its stake in Stryker Corporation by 600.6% in the 1st quarter. SG Americas Securities LLC now owns 412,340 shares of the medical technology company’s stock worth $54,285,000 after acquiring an additional 353,486 shares in the last quarter. Finally, Morgan Stanley grew its stake in Stryker Corporation by 17.9% in the 1st quarter. Morgan Stanley now owns 2,144,472 shares of the medical technology company’s stock worth $282,320,000 after acquiring an additional 325,661 shares in the last quarter. Institutional investors and hedge funds own 74.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/18/stryker-corporation-syk-shares-sold-by-boston-private-wealth-llc.html.

In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,429 shares of company stock valued at $3,686,927. 7.40% of the stock is owned by company insiders.

A number of equities analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. BidaskClub downgraded shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Canaccord Genuity restated a “buy” rating and issued a $155.00 target price (down from $158.00) on shares of Stryker Corporation in a research note on Thursday, August 24th. Argus reiterated a “buy” rating and set a $160.00 price objective on shares of Stryker Corporation in a research note on Tuesday, August 29th. Finally, Zacks Investment Research upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price objective on the stock in a research note on Monday, July 17th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $145.73.

Stryker Corporation (NYSE SYK) opened at 143.88 on Monday. The stock has a market cap of $53.82 billion, a PE ratio of 32.12 and a beta of 0.81. Stryker Corporation has a one year low of $106.48 and a one year high of $148.84. The company’s 50 day moving average is $143.77 and its 200 day moving average is $138.65.

Stryker Corporation (NYSE:SYK) last issued its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.39 EPS. On average, equities research analysts expect that Stryker Corporation will post $6.46 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be paid a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s dividend payout ratio is currently 37.95%.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.